ERAS vs. NLTX, KMDA, VRCA, CTNM, RENB, AKBA, CRMD, EPIX, TERN, and XOMA
Should you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Neoleukin Therapeutics (NLTX), Kamada (KMDA), Verrica Pharmaceuticals (VRCA), Contineum Therapeutics (CTNM), Renovaro (RENB), Akebia Therapeutics (AKBA), CorMedix (CRMD), ESSA Pharma (EPIX), Terns Pharmaceuticals (TERN), and XOMA (XOMA). These companies are all part of the "pharmaceutical preparations" industry.
Neoleukin Therapeutics (NASDAQ:NLTX) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership.
Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
Neoleukin Therapeutics' return on equity of -35.60% beat Erasca's return on equity.
52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 29.8% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Erasca had 2 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 2 mentions for Erasca and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.75 beat Erasca's score of 0.00 indicating that Erasca is being referred to more favorably in the news media.
Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.
Neoleukin Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 0.44%. Erasca has a consensus target price of $7.83, suggesting a potential upside of 316.67%. Given Neoleukin Therapeutics' higher possible upside, analysts plainly believe Erasca is more favorable than Neoleukin Therapeutics.
Neoleukin Therapeutics received 35 more outperform votes than Erasca when rated by MarketBeat users. However, 60.00% of users gave Erasca an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
Summary
Erasca beats Neoleukin Therapeutics on 11 of the 14 factors compared between the two stocks.
Get Erasca News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
